The Business Research Company’s report on the Amusement Parks Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
Which emerging drivers are set to accelerate the growth of the candidiasis therapeutics market further?
The growing incidence of fungal infections is expected to propel the growth of the candidiasis therapeutics market going forward. Fungal infections are illnesses caused by various fungi that can affect the skin, mucous membranes, and internal organs in humans. The rising number of individuals with compromised immune systems and individuals with fungal infections increases the susceptibility to candidiasis, creating opportunities for manufacturers to develop and supply specialized and more effective antifungal drugs that target the underlying fungal pathogens, relieve symptoms, prevent complications, promote patient recovery, reduce the spread of Candida infections within healthcare facilities, and contribute to better patient outcomes. For instance, in January 2024, according to the University of Minnesota, a US-based research university, fungal infections lead to more than 3.75 million deaths annually, with approximately 2.55 million of these deaths directly attributable to fungal diseases. Therefore, the growing incidence of fungal infections will drive the growth of the candidiasis therapeutics market.
Candidiasis Therapeutics Market Driver: Rising Clinical Trials Fueling Advancements In Candidiasis Therapeutics Market
The increasing number of clinical trials is expected to propel the growth of the candidiasis therapeutics market going forward. Clinical trials are research studies conducted to evaluate the safety and effectiveness of new medical treatments, interventions, drugs, or devices in humans. Clinical trials play a pivotal role in the development of candidiasis therapeutics by providing a systematic and rigorous process to evaluate the safety and efficacy of potential treatments. For instance, in May 2023, according to ClinicalTrials.gov, a part of the National Institutes of Health (NIH), a US-based government agency responsible for conducting and supporting medical research, in 2023, around 437,533 clinical trials were registered, compared to 399,499 registered studies in 2022 in all 50 states of the United States and across 221 countries. Therefore, the increasing number of clinical trials is driving the growth of the candidiasis therapeutics market.
Access Your Free Sample of the Global Amusement Parks Global Market Report 2025 Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13182&type=smp
What are the key factors influencing the forecasted market size of the candidiasis therapeutics industry?
The candidiasis therapeutics market size has grown steadily in recent years. It will grow from $3.19 billion in 2024 to $3.3 billion in 2025 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to increased incidence of candidiasis, antibiotic use and resistance, hospital-acquired infections, shift in fungal resistance patterns, awareness and education programs.
The candidiasis therapeutics market size is expected to see steady growth in the next few years. It will grow to $3.83 billion in 2029 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to precision medicine approaches, global antifungal stewardship programs, increasing prevalence of candida auris, global efforts against antifungal resistance. Major trends in the forecast period include advancements in drug delivery technologies, telemedicine and remote patient monitoring, patient-centric care, combination therapies, collaborative research initiatives.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=13182&type=smp
Who are the leading competitors in the candidiasis therapeutics market?
Major companies operating in the candidiasis therapeutics market report are Pfizer Inc., Biocon Limited, Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc., GSK plc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Bruker Corporation, Lupin Limited, Galapagos NV, Basilea Pharmaceutica Ltd., WOCKHARDT Limited, Pacgen Life Science Corporation, Cidara Therapeutics Inc., Ablynx NV, Amplyx Pharmaceuticals Inc., NovaDigm Therapeutics Inc., SCYNEXIS Inc., Medivir AB, Mycovia Pharmaceuticals Inc., NovaBiotics Inc., Matinas BioPharma Holdings Inc.
Which emerging trends are set to transform the candidiasis therapeutics market landscape?
Major companies operating in the candidiasis therapeutics market are developing innovative drugs such as BREXAFEMME (ibrexafungerp tablets) to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in adult women. BREXAFEMME (ibrexafungerp tablets) is an oral, non-azole medication for the treatment of vulvovaginal candidiasis (VVC) and the reduction of the incidence of recurrent vulvovaginal candidiasis (RVVC), also known as chronic yeast infections. For instance, in December 2022, Scynexis Inc., a US-based pharmaceutical company, received the US Food and Drug Administration (FDA) approval for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), also known as chronic yeast infections. BREXAFEMME works by blocking the growth of Candida albicans, the fungus that causes VVC. Moreover, it is a safe and effective treatment option for vulvovaginal candidiasis (VVC). It is also available only by prescription, with a recommended dose of one 150-mg capsule taken orally once daily for one day.
How do different geographies compare in terms of market share and growth potential in the candidiasis therapeutics market?
North America was the largest region in the candidiasis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candidiasis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report
Which major segments of the candidiasis therapeutics market are experiencing the fastest growth?
The candidiasis therapeutics market covered in this report is segmented –
1) By Treatment Type: Medication, Surgery, Other Treatments
2) By Anatomy Type: Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis
3) By Mode Of Administration: Injectable, Oral, Other Mode Of Administrations
4) By Patient Population: Adults, Pediatrics
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Medication: Antifungal Drugs, Topical Treatments, Systemic Treatments
2) By Surgery: Surgical Debridement, Organ Removal
3) By Other Treatments: Probiotics, Home Remedies, Lifestyle Modifications
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13182
How is the candidiasis therapeutics market defined?
Candidiasis is a fungal infection caused by the overgrowth of Candida species that naturally reside in the human body, particularly in the mouth, throat, gut, and genital area. Treatment for candidiasis typically involves antifungal medications, which can be topical (applied to the affected area) or oral (taken by mouth), depending on the severity and location of the infection.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
